ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Cis- and Trans-Regulatory Factors Independently Shape Phenotypic Heterogeneity of Retinitis Pigmentosa.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Retinitis pigmentosa (RP) is a group of retinal inherited diseases characterized by substantial clinical heterogeneity, even among individuals carrying the same pathogenic mutation. In this study, we identified two distinct genetic mechanisms influencing RP severity using a transgenic zebrafish model expressing the human rhodopsin S334X mutation. The first mechanism is tightly linked to RP onset and results in a benign phenotype. Whole-genome sequencing revealed a 3-base-pair insertion upstream of the transgene, specific to the benign line, acting as a cis-regulatory variant that suppresses transgene expression, as validated by RT-qPCR, Western blot and luciferase assays. The second mechanism operates independently of RP onset and modifies the benign phenotype toward a more severe presentation. This segregation was observed in approximately half of the offspring derived from specific individuals within the S334X-benign line, consistent with a Mendelian ratio, suggesting a dominant trans-acting factor. Together, these findings provide the first in vivo evidence that both cis- and trans-regulatory elements independently and cooperatively modulate RP phenotypes within a shared genetic background. They clearly establish the existence of genetic modifiers as key contributors to disease variability, offering new directions for personalized RP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.